GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (LTS:0RK9) » Definitions » EV-to-EBIT

Alligator Bioscience AB (LTS:0RK9) EV-to-EBIT : -0.94 (As of May. 30, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Alligator Bioscience AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alligator Bioscience AB's Enterprise Value is kr139.66 Mil. Alligator Bioscience AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-148.98 Mil. Therefore, Alligator Bioscience AB's EV-to-EBIT for today is -0.94.

The historical rank and industry rank for Alligator Bioscience AB's EV-to-EBIT or its related term are showing as below:

LTS:0RK9' s EV-to-EBIT Range Over the Past 10 Years
Min: -32.04   Med: -2.49   Max: 0.41
Current: -0.94

During the past 11 years, the highest EV-to-EBIT of Alligator Bioscience AB was 0.41. The lowest was -32.04. And the median was -2.49.

LTS:0RK9's EV-to-EBIT is ranked worse than
100% of 477 companies
in the Biotechnology industry
Industry Median: 8.26 vs LTS:0RK9: -0.94

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alligator Bioscience AB's Enterprise Value for the quarter that ended in Mar. 2025 was kr143.19 Mil. Alligator Bioscience AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-148.98 Mil. Alligator Bioscience AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -104.05%.


Alligator Bioscience AB EV-to-EBIT Historical Data

The historical data trend for Alligator Bioscience AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alligator Bioscience AB EV-to-EBIT Chart

Alligator Bioscience AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.33 -2.11 -1.40 -1.63 -0.79

Alligator Bioscience AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.57 -3.71 -4.02 -0.79 -0.87

Competitive Comparison of Alligator Bioscience AB's EV-to-EBIT

For the Biotechnology subindustry, Alligator Bioscience AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's EV-to-EBIT falls into.


;
;

Alligator Bioscience AB EV-to-EBIT Calculation

Alligator Bioscience AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=139.659/-148.978
=-0.94

Alligator Bioscience AB's current Enterprise Value is kr139.66 Mil.
Alligator Bioscience AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-148.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alligator Bioscience AB  (LTS:0RK9) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alligator Bioscience AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-148.978/143.1852
=-104.05 %

Alligator Bioscience AB's Enterprise Value for the quarter that ended in Mar. 2025 was kr143.19 Mil.
Alligator Bioscience AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-148.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alligator Bioscience AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alligator Bioscience AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Alligator Bioscience AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheeletorget 1, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Its drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator Bioscience AB Headlines

No Headlines